


Co-administration of influenza and COVID-19 vaccinations

NISEC January 2024




Co-administration data needed to inform 2021/22 seasonal vaccine programme




‘Avoid incorrect attribution of side effects’ UKHSA ‘abundance of caution’ CDC

Trial Design & Schema


Multicentre RCT with Blinding






COVID-19 and influenza vaccines tested reflected available products

S-protein Ig concentrations after co-administration were non-inferior to COVID-19 vaccine alone




Lazarus et al Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial

A 25% increase in the proportion of individuals reporting grade 2/3 systemic reaction considered acceptable



Supplementary Figure 2 Seven-day profiles of systemic adverse reactions following D0




Only 9 participants stated that they
would not have concomitant
vaccination in the future
(only 3 received concomitant
vaccination)

Only 11(3.1%) of those employed
had time off work due to vaccine
related adverse events
(only 7 received concomitant
vaccination)





19 Nov 2021

S-protein IgG detected in saliva for both vaccines



S-protein Ig(G) response measured by 3 assays



Acknowledgements



Primary care sites
Knowle House Surgery
Newquay Health centre
The Alverton Practice